<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02879968</url>
  </required_header>
  <id_info>
    <org_study_id>PrinceSongklaU</org_study_id>
    <nct_id>NCT02879968</nct_id>
  </id_info>
  <brief_title>Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer</brief_title>
  <official_title>Correlation Between Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Correlation between serum squamous cell carcinoma antigen level and tumor volume in Head and
      Neck Cancer is to determine a correlation between level of serum squamous cell carcinoma
      antigen and tumor volume in Head and Neck Caner measured by cross-sectional imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a cross-sectional study. A single measurement of serum squamous cell carcinoma
      antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.

      The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC
      (Abbott).

      The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient
      is calculated with the typical ellipsoid formula.

      Correlation between both parameters will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between serum squamous cell carcinoma antigen and tumor volume</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Head and Neck squamous cell carcinoma</arm_group_label>
    <description>A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.
The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).
The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional study</intervention_name>
    <arm_group_label>Head and Neck squamous cell carcinoma</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum squamous cell carcinoma antigen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Head and Neck squamous cell carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinoma in Head and Neck

          -  Getting a cross-sectional imaging of Head and Neck within 2 weeks of collecting serum
             squamous cell carcinoma antigen

        Exclusion Criteria:

          -  Metastatic disease

          -  Accompanied Non-Head and Neck squamous cell carcinoma

          -  Nasopharyngeal, thyroid, salivary, nose and paranasal sinus carcinoma

          -  Skin disease: eczema, erythrodermic epidermitis, pemphigus, and psoriasis

          -  Pulmonary disease: tuberculosis, adult respiratory distress syndrome, pulmonary
             infiltration with eosinophilia, sarcoidosis, and bronchogenic cyst

          -  Renal failure

          -  Using antihistamine eye drops
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kitti Jantharapattana, M.D.</last_name>
    <phone>6674451390</phone>
    <email>kittient@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teerapol Kotamnivates, M.D.</last_name>
    <phone>6674451390</phone>
    <email>hankyent@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Prince of Songkla University</name>
      <address>
        <city>Hatyai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kitti Jantharapattana, M.D.</last_name>
      <phone>6674451390</phone>
      <email>kittient@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Teerapol Kotamnivates, M.D.</last_name>
      <phone>6674451390</phone>
      <email>hankyent@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kitti Jantharapattana, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teerapol Kotamnivates, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siriporn Hirunpat, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roongrueng Jarumanokul</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Kitti Jantharapattana, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>serum squamous cell carcinoma antigen</keyword>
  <keyword>tumor volume</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serpins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

